Lilly Completes Acquisition of Sigilon Therapeutics

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ: SGTX). The acquisition allows Lilly to continue researching and developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. "Make life better ...

Related Keywords

Canaccord Genuity ,Eli Lilly ,Ruth Gimeno ,Morgan ,Securities Exchange ,Corporation Law ,Instagram ,Linkedin ,Sigilon Therapeutics Inc ,Nasdaq ,Twitter ,Lewis Bockius ,Lazard ,Ropes Gray ,Facebook ,Sigilon Therapeutics ,Merger Agreement ,Cash Consideration ,General Corporation Law ,Offer Price ,Select Market ,Securities Exchange Act ,